Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BeOne Medicines's Enterprise Value is $26,394 Mil.
BeOne Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $756 Mil. Therefore, BeOne Medicines's EV-to-EBIT ratio for today is 34.91.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, BeOne Medicines's Enterprise Value is $26,394 Mil.
BeOne Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $906 Mil. Therefore, BeOne Medicines's EV-to-EBITDA ratio for today is 29.13.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, BeOne Medicines's Enterprise Value is $26,394 Mil.
BeOne Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $5,739 Mil. Therefore, BeOne Medicines's EV-to-Revenue ratio for today is 4.60.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, BeOne Medicines's Enterprise Value is $26,394 Mil.
BeOne Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $1,094 Mil. Therefore, BeOne Medicines's EV-to-FCF ratio for today is 24.13.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
BeOne Medicines (NAS:ONC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
BeOne Medicines's current Enterprise Value is $26,394 Mil.
BeOne Medicines's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $756 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
BeOne Medicines's current Enterprise Value is $26,394 Mil.
BeOne Medicines's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $906 Mil.
BeOne Medicines's current Enterprise Value is $26,394 Mil.
BeOne Medicines's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5,739 Mil.
BeOne Medicines's current Enterprise Value is $26,394 Mil.
BeOne Medicines's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,285 Mil.
BeOne Medicines's current Enterprise Value is $26,394 Mil.
BeOne Medicines's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,094 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines Enterprise Value Related Terms
BeOne Medicines Enterprise Value Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ONC vs RVMD, RPRX, BNTX: Enterprise Value Comparison
For the Biotechnology subindustry, BeOne Medicines's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Enterprise Value distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
BeOne Medicines's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (ONC) has a Enterprise Value of $26,394 Mil as of Jun. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Enterprise Value too high?
BeOne Medicines' current Enterprise Value is $26,394 Mil. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Enterprise Value compare to RVMD and RPRX?
BeOne Medicines' Enterprise Value of $26,394 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Enterprise Value is $26,394 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $366.06, compared to a current price of $280.00 — trading 23.5% below its estimated fair value. The current Enterprise Value is $26,394 Mil. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Enterprise Value is $26,394 Mil as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $280.00 is trading 23.5% below its estimated GF Value™ of $366.06.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for ONC:
Enterprise Value: $26,394 Mil
GF Value™: $366.06 vs. price of $280.00 (23.5% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for ONC
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
